Myocarditis related SARS-CoV-2 infection or vaccination: an expert consensus statement on its diagnosis and management

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has revealed several cardiovascular complications, including myocarditis caused by SARS-CoV-2 infection (COVID-19) or after messenger RNA vaccine administration. Because of the high prevalence of COVID-19, the expansion of vac...

Descripción completa

Detalles Bibliográficos
Autores principales: Barreiro-Pérez, Manuel, Pastor Pueyo, Pablo, Raposeiras-Roubín, Sergio, Montero Corominas, Dolores, Uribarri, Aitor, Eiros Bachiller, Rocío, Rozado Castaño, José, García-Cuenllas Álvarez, Luisa, Serratosa Fernández, Luis, Domínguez, Fernando, Pascual Figal, Domingo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. 2023
Materias:
Special Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008093/
https://www.ncbi.nlm.nih.gov/pubmed/36914023
http://dx.doi.org/10.1016/j.rec.2023.01.011
Descripción
Sumario:The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has revealed several cardiovascular complications, including myocarditis caused by SARS-CoV-2 infection (COVID-19) or after messenger RNA vaccine administration. Because of the high prevalence of COVID-19, the expansion of vaccination programs, and the appearance of new information on myocarditis in these contexts, there is a need to condense the knowledge acquired since the start of the pandemic. To meet this need, this document was drafted by the Myocarditis Working Group of the Heart Failure Association of the Spanish Society of Cardiology, with the collaboration of the Spanish Agency for Medicines and Health Products (AEMPS). The document aims to address the diagnosis and treatment of cases of myocarditis associated with SARS-CoV-2 infection or messenger RNA vaccine administration.

Ejemplares similares